Evidence map›Paper›PMID 12420216›Full record

ArticleOncogene2002

Src activation regulates anoikis in human colon tumor cell lines.

T Christopher Windham, Nila U Parikh, Doris R Siwak, Justin M Summy, David J McConkey, Alan J Kraker, Gary E Gallick

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 212 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Cell death in the gut epithelium and implications for chronic inflammation.Nature reviews. Gastroenterology & hepatology · 2020
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

T Christopher WindhamDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas, TX 77030, USA.
Nila U Parikh
Doris R Siwak
Justin M Summy
David J McConkey
Alan J Kraker
Gary E Gallick
The University of Texas MD Anderson Cancer Center · USPfizer (United States) · US

Funding

TRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2M
SRC KINASES IN COLON TUMORIGENESIS AND METASTASISR01CA065527 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI GALLICK, GARY E · 1996 to 2003
$881k
SYNTHESIS OF ACTIVE SITE-DIRECTED SRC INHIBITORSU19CA053617 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI GALLICK, GARY E · 1996 to 2000
$807k
DISCOVERY AND DEVELOPMENT OF TYROSINE KINASE INHIBITORSU01CA053617 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI LEVIN, VICTOR A · 1990 to 1994
–
NCI NIH HHS CA53617NCI NIH HHS CA65527NCI NIH HHS T32CA09599
6 · The paper itself

Abstract

Src is a non-receptor protein tyrosine kinase, the expression and activity of which is increased in >80% of human colon cancers with respect to normal colonic epithelium. Previous studies from this and other laboratories have demonstrated that Src activity contributes to tumorigenicity of established colon adenocarcinoma cell lines. Src participates in the regulation of many signal transduction pathways, among which are those leading to cellular survival. In this study, we addressed the potential role of Src activation to a specific aspect of tumor cell survival, resistance to detachment-induced apoptosis (anoikis). Using five colon tumor cell lines with different biologic properties and genetic alterations, we demonstrate that expression and activity of Src corresponds with resistance to anoikis. Enforced expression of activated Src in subclones of SW480 cells (of low intrinsic Src expression and activity) increases resistance to anoikis; whereas decreased Src expression in HT29 cells (of high Src expression and activity) by transfection with anti-sense Src expression vectors increases susceptibility to anoikis. In contrast, increasing or decreasing Src expression had no effect on susceptibility to staurosporine-induced apoptosis in attached cells. PD173955, a Src family-specific tyrosine kinase inhibitor, increases the susceptibility of HT29 cells to anoikis in a dose- and time-dependent manner. Increasing Src expression and activity led to increased phosphorylation of Akt, a mediator of cellular survival pathways, whereas decreasing Src activity led to decreased Akt phosphorylation. In colon tumor cells with high Src activity, the PI3 kinase inhibitor LY 294002 sensitized cells to anoikis. These results suggest that Src activation may contribute to colon tumor progression and metastasis in part by activating Akt-mediated survival pathways that decrease sensitivity of detached cells to anoikis.

Indexed as

Protein Serine-Threonine KinasesAdenocarcinomaAmino Acid SubstitutionAnoikisApoptosisbcl-X ProteinCaspase 3CaspasesCell AdhesionCell CycleChromonesColonic NeoplasmsDisease ProgressionEnzyme ActivationEnzyme InhibitorsGene Expression Regulation, Neoplastic2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAKT1 protein, humanBCL2L1 protein, humanbcl-X ProteinCASP3 protein, humanCaspase 3CaspasesChromonesEnzyme InhibitorsMorpholinesNeoplasm ProteinsPD 173955Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins pp60(c-src)PyridonesPyrimidinesRecombinant Fusion ProteinsStaurosporine

Identifiers

PMID12420216
OpenAlexW2330746655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.